Sheryl Stevenson

Caroline Baumal, MD, highlights results from the Phase 3 YOSEMITE and RHINE trials, providing an overview of the efficacy, safety and durability of faricimab in DME.

Ophthalmologists and industry executives share what lingers on their minds at the end of the day.

George O. Waring IV, MD, FACS, discusses the latest results from the GEMINI 1 clinical trial (by Allergan, an Abbvie company) of AGN-190584 (pilocarpine 1.25%) ophthalmic solution for the treatment of presbyopia.

Javier Zarranz-Ventura MD, PhD, FEBO, discusses the key highlights from his presentation on a clinical investigation of suitable naïve versus pre-treated DME patients, and what it means for future research.

Quan Dong Nguyen, MD, MSc, FARVO, FASRS, highlights his presentation regarding new biological treatments of posterior uveitis.

George O. Waring IV, MD, FACS, discusses the latest results from the GEMINI 1 clinical trial of AGN-190584 (pilocarpine 1.25%) ophthalmic solution for the treatment of presbyopia.

Chuck Hess shares an update on Bausch + Lomb's latest developments in surgical technology, as well as how the company has adapted its operations during the pandemic.

Jag Dosanjh, senior vice president of U.S. Eye Care, Allergan, an AbbVie company, offers a preview of the company's latest innovations, developments, and what attendees can look forward to at ASCRS 2021.

Oluwatosin U. Smith, MD, Glaucoma Associates of Texas, offers an update on optimization and surgical modifications of newer glaucoma surgeries in preop and postop settings.

Christopher Starr, MD, discusses key points from his virtual ARVO 2021 presentation regarding dry eye disease flares, including a rapid readout assessment of 10 years' worth of world literature to analyze studies in which the inflammatory disease's condition are categorized.

Jeffrey Gemi, MD, Ora Inc., speaks on the highlights from his presentation comparing Schirmer's test with other clinical outcomes in dry eye.

Find out how one eye care practice has found success in adapting their services to ensure staff/patient safety throughout the pandemic.

In this latest EyePod episode, John H. Merey, MD, possibly one of the last Holocaust survivors still in the practice of ophthalmology, shares his experience.

Ted Leng, MD, MS, Byers Eye Institute at Stanford, and medical advisor for Verana Health, talks about data insights for retinal surgeons. Steven D. Schwartz, MD, Stein Eye Institute, UCLA, highlights his AAO presentation, “New Insight into Real-World U.S. Injection Data."

Chris Brittain, MBBS, BSc, MBA, MRCOphth, vice president and global head of ophthalmology product development for Genentech, provides an overview of the company’s podium presentations from the PDS with ranibizumab to faricimab.

John J. Grande, CFP, and John S. Grande, CFP, discuss why ophthalmologists should be focusing on having a financial plan ahead of a second wave in the ongoing pandemic.

Ranya Habash, MD, discusses telemedicine in ophthalmology amid the ongoing pandemic.

Susan Coultas, PhD, and Preeya Gupta, MD, discuss Kala Pharmaceuticals’ dry eye product candidate in a poster presentation during the 2020 Women in Ophthalmology virtual summer symposium.

Retina specialists Caesar Luo, MD, of Bay Area Retina Associates (Walnut Creek, CA) and S.K. Steven Houston III, MD, of Florida Retina Institute, share their outlooks on retina innovation in the "year of the eye" amid a global pandemic.

S.K. Steven Houston III, MD, discusses retina innovations in use in his practice, including the NGENUITY 1.4 upgrade from Alcon, and adapting to ever-changing operating room spacing and set-up in the COVID-19 environment

Theresa Heah, MD, provides an update on AsclepiX’s AXT107, which is derived from a cryptic peptide within collagen IV that works by activating naturally existing, homeostatic mechanisms of angiogenesis.

ASRS 2020: Josh Anderson speaks on the highlights from Alcon, including new data on the performance benefits of the Hypervit dual blade 20,000 cpm probe and the launch of the NGENUITY 1.4 upgrade.

Philadelphia-In an uncertain economic climate, the ophthalmic market can take stock in knowing it is alive and well, according to Kenneth P. Taylor, an independent industry consultant.